QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

MMSITICKER

Merit Medical Systems Inc.

INSUFFICIENT DATA stock

Congress has disclosed 1 buy and 1 sell of MMSI (Merit Medical Systems Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

1
Buy
1
Sell
+0
Net
2
Active politicians

Round-trip watch Still on the books

Members who disclosed buying MMSI and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Lisa McClain 2025-07-22 $84.47 $86.24 +2.1% ↩ near entry

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
32.27
no sector median
how it's calculated
P/E = price ÷ earnings per share
$86.24 ÷ $2.67 = 32.27
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
2.96
no sector median
how it's calculated
P/B = price ÷ book value per share
$86.24 ÷ $29.12 = 2.96
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
15.85
no sector median
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA
($5.2B + $0.2B net debt) ÷ $0.3B = $5.4B ÷ $0.3B = 15.85
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

2 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Lisa McClain House BUY ◆ insider divergence · moderate Spouse · Charles Schwab Brokerage Account 924 2025-07-22 22 days +2.0% $1K–$15K
0.1% of NW
63.9 ↗ filing
Steve Chabot House SELL Self 2015-05-26 0 days — $15K–$50K 93.7 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in MMSI — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

0
Congress trades with insider convergence
1
…with insider divergence
61
Insider open-market trades

Of the congressional trades in MMSI, 0 coincided with corporate insiders moving the same way within 60 days, and 1 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-08-24 Peterson Neil W. C-suite SELL $678K ↗ EDGAR
2026-08-04 Peterson Neil W. C-suite SELL $1.8M ↗ EDGAR
2026-05-11 Smith Christian Adam C-suite BUY $99K ↗ EDGAR
2026-05-07 Lloyd Brian G. C-suite BUY $125K ↗ EDGAR
2026-05-07 Ward Lynne N. Director SELL $313K ↗ EDGAR
2026-05-06 Aronson Martha Goldberg C-suite BUY $121K ↗ EDGAR
2026-05-06 Parra Raul Jr. C-suite BUY $92K ↗ EDGAR
2026-05-05 Voigt Michel J. C-suite BUY $136K ↗ EDGAR
2026-01-06 Peterson Neil W. C-suite SELL 10b5-1 $450K ↗ EDGAR
2025-11-25 Lampropoulos Fred P. Director SELL $880K ↗ EDGAR
2025-11-21 Lampropoulos Fred P. Director SELL $2.2M ↗ EDGAR
2025-11-20 Lampropoulos Fred P. Director SELL $1.7M ↗ EDGAR
2025-11-18 Lampropoulos Fred P. Director SELL $424K ↗ EDGAR
2025-08-22 Ward Lynne N. Director SELL $266K ↗ EDGAR
2025-08-11 Ward Lynne N. Director SELL $207K ↗ EDGAR
2025-06-13 Parra Raul Jr. C-suite SELL $1.4M ↗ EDGAR
2025-06-10 Lampropoulos Fred P. C-suite SELL $38K ↗ EDGAR
2025-06-05 Lampropoulos Fred P. C-suite SELL $952K ↗ EDGAR
2025-06-02 McDonnell Michael R. Director SELL 10b5-1 $165K ↗ EDGAR
2025-05-30 Lampropoulos Fred P. C-suite SELL $951K ↗ EDGAR
2025-05-30 Floyd David Director SELL 10b5-1 $331K ↗ EDGAR
2025-05-30 McDonnell Michael R. Director SELL 10b5-1 $165K ↗ EDGAR
2025-05-27 LAMPROPOULOS FRED P C-suite SELL $1.9M ↗ EDGAR
2025-05-15 Millner F. Ann Director SELL 10b5-1 $2.0M ↗ EDGAR
2025-04-01 Peterson Neil C-suite SELL 10b5-1 $523K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-08-24 Peterson Neil W. C-suite SELL $678K
◆ insider 2026-08-04 Peterson Neil W. C-suite SELL $1.8M
◆ insider 2026-05-11 Smith Christian Adam C-suite BUY $99K
◆ insider 2026-05-07 Lloyd Brian G. C-suite BUY $125K
◆ insider 2026-05-07 Ward Lynne N. Director SELL $313K
◆ insider 2026-05-06 Aronson Martha Goldberg C-suite BUY $121K
◆ insider 2026-05-06 Parra Raul Jr. C-suite BUY $92K
◆ insider 2026-05-05 Voigt Michel J. C-suite BUY $136K
◆ insider 2026-01-06 Peterson Neil W. C-suite 10b5-1 SELL $450K
◆ insider 2025-11-25 Lampropoulos Fred P. Director SELL $880K
◆ insider 2025-11-21 Lampropoulos Fred P. Director SELL $2.2M
◆ insider 2025-11-20 Lampropoulos Fred P. Director SELL $1.7M
◆ insider 2025-11-18 Lampropoulos Fred P. Director SELL $424K
◆ insider 2025-08-22 Ward Lynne N. Director SELL $266K
◆ insider 2025-08-11 Ward Lynne N. Director SELL $207K
Congress 2025-07-22 Lisa McClain BUY $1K–$15K
◆ insider 2025-06-13 Parra Raul Jr. C-suite SELL $1.4M
◆ insider 2025-06-10 Lampropoulos Fred P. C-suite SELL $38K
◆ insider 2025-06-05 Lampropoulos Fred P. C-suite SELL $952K
◆ insider 2025-06-02 McDonnell Michael R. Director 10b5-1 SELL $165K
◆ insider 2025-05-30 Lampropoulos Fred P. C-suite SELL $951K
◆ insider 2025-05-30 Floyd David Director 10b5-1 SELL $331K
◆ insider 2025-05-30 McDonnell Michael R. Director 10b5-1 SELL $165K
◆ insider 2025-05-27 LAMPROPOULOS FRED P C-suite SELL $1.9M

FAQ Common questions

How much has Congress traded MMSI?

1 disclosed buys and 1 sells of MMSI (Merit Medical Systems Inc.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade MMSI?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.